Henry James International Management Inc. purchased a new position in shares of GALAPAGOS NV/S (NASDAQ:GLPG) during the 3rd quarter, HoldingsChannel reports. The institutional investor purchased 20,009 shares of the biotechnology company’s stock, valued at approximately $2,250,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of GLPG. Alps Advisors Inc. lifted its position in GALAPAGOS NV/S by 7.7% during the 2nd quarter. Alps Advisors Inc. now owns 73,389 shares of the biotechnology company’s stock worth $6,765,000 after buying an additional 5,234 shares in the last quarter. Provident Investment Management Inc. acquired a new position in GALAPAGOS NV/S during the 2nd quarter worth about $249,000. Stanley Laman Group Ltd. acquired a new position in GALAPAGOS NV/S during the 2nd quarter worth about $720,000. Federated Investors Inc. PA lifted its position in GALAPAGOS NV/S by 9.3% during the 2nd quarter. Federated Investors Inc. PA now owns 1,424,763 shares of the biotechnology company’s stock worth $131,335,000 after buying an additional 121,415 shares in the last quarter. Finally, Employees Retirement System of Texas lifted its position in GALAPAGOS NV/S by 26.8% during the 2nd quarter. Employees Retirement System of Texas now owns 71,000 shares of the biotechnology company’s stock worth $6,545,000 after buying an additional 15,000 shares in the last quarter. Institutional investors and hedge funds own 18.13% of the company’s stock.

Several research analysts recently issued reports on the stock. Credit Suisse Group upgraded shares of GALAPAGOS NV/S from a “neutral” rating to an “outperform” rating in a research report on Thursday. Zacks Investment Research raised GALAPAGOS NV/S from a “hold” rating to a “buy” rating and set a $115.00 price objective for the company in a report on Tuesday, December 11th. Raymond James initiated coverage on GALAPAGOS NV/S in a report on Wednesday, November 14th. They set a “strong-buy” rating and a $157.00 price objective for the company. ValuEngine raised GALAPAGOS NV/S from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 10th. Finally, Morgan Stanley boosted their price objective on GALAPAGOS NV/S from $127.00 to $131.00 and gave the stock an “overweight” rating in a report on Monday, November 5th. Three analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. GALAPAGOS NV/S presently has an average rating of “Buy” and an average target price of $121.78.

Shares of NASDAQ:GLPG opened at $104.12 on Friday. GALAPAGOS NV/S has a 1-year low of $87.36 and a 1-year high of $122.28.

GALAPAGOS NV/S (NASDAQ:GLPG) last announced its quarterly earnings data on Friday, October 26th. The biotechnology company reported $0.33 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.70. The firm had revenue of $119.99 million during the quarter, compared to analysts’ expectations of $82.15 million. GALAPAGOS NV/S had a negative return on equity of 7.66% and a negative net margin of 30.65%. As a group, research analysts anticipate that GALAPAGOS NV/S will post -1.72 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.thecerbatgem.com/2018/12/16/20009-shares-in-galapagos-nv-s-glpg-acquired-by-henry-james-international-management-inc.html.

GALAPAGOS NV/S Profile

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

Recommended Story: What Is An Exchange-Traded Fund (ETF)?

Want to see what other hedge funds are holding GLPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GALAPAGOS NV/S (NASDAQ:GLPG).

Institutional Ownership by Quarter for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.